Merck & Co. (MRK)
(Real Time Quote from BATS)
$115.19 USD
+0.23 (0.20%)
Updated Sep 25, 2024 03:26 PM ET
4-Sell of 5 4
C Value C Growth A Momentum B VGM
Price, Consensus and EPS Surprise
MRK 115.19 +0.23(0.20%)
Will MRK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MRK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRK
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal
Company News for Sep 24, 2024
MRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers
Merck (MRK) Stock Moves -0.05%: What You Should Know
Other News for MRK
When Buffett Meets Bannister
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
Merck?s KEYTRUDA? (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
Merck fails in late-stage trial for Keytruda combo in colon cancer
Wall Street Lunch: China-Linked Hackers Get Access To Some U.S. Providers